• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
In the Cradle of Pharmacometric Methodology: Introducing Population PKPD Modeling, Simultaneous Analysis, and the Effect-Compartment Model-Commentary on Sheiner et al.在药代动力学方法的摇篮中:介绍群体药代动力学-药效学建模、同步分析和效应室模型——对谢纳等人的评论
Clin Pharmacol Ther. 2025 Jun;117(6):1516-1532. doi: 10.1002/cpt.3663.
2
Population PKPD modelling of the long-term hypoglycaemic effect of gliclazide given as a once-a-day modified release (MR) formulation.格列齐特一日一次缓释制剂长期降血糖作用的群体药代动力学-药效学建模。
Br J Clin Pharmacol. 2003 Feb;55(2):147-57. doi: 10.1046/j.1365-2125.2003.01751.x.
3
Methods and software tools for design evaluation in population pharmacokinetics-pharmacodynamics studies.群体药代动力学-药效学研究中设计评估的方法与软件工具
Br J Clin Pharmacol. 2015 Jan;79(1):6-17. doi: 10.1111/bcp.12352.
4
A semicompartmental modeling approach for pharmacodynamic data assessment.一种用于药效学数据评估的半房室建模方法。
J Pharmacokinet Biopharm. 1995 Jun;23(3):307-22. doi: 10.1007/BF02354287.
5
Pharmacometric and statistical considerations for dose optimization.剂量优化的药代动力学和统计学考量
CPT Pharmacometrics Syst Pharmacol. 2025 Feb;14(2):279-291. doi: 10.1002/psp4.13271. Epub 2024 Nov 6.
6
Population Pharmacokinetics of an Extended-Release Formulation of Exenatide Following Single- and Multiple-Dose Administration.艾塞那肽缓释制剂单剂量和多剂量给药后的群体药代动力学
AAPS J. 2017 Mar;19(2):487-496. doi: 10.1208/s12248-016-9975-1. Epub 2016 Nov 28.
7
Modeling of delays in PKPD: classical approaches and a tutorial for delay differential equations.药代动力学-药效学中的延迟建模:经典方法及延迟微分方程教程
J Pharmacokinet Pharmacodyn. 2014 Aug;41(4):291-318. doi: 10.1007/s10928-014-9368-y. Epub 2014 Aug 21.
8
Understanding and applying pharmacometric modelling and simulation in clinical practice and research.在临床实践和研究中理解并应用药代动力学建模与模拟。
Br J Clin Pharmacol. 2017 Feb;83(2):247-254. doi: 10.1111/bcp.13119. Epub 2016 Sep 29.
9
Population PKPD of voclosporin in renal allograft patients.肾移植患者中voclosporin的群体药代动力学-药效学
J Clin Pharmacol. 2014 May;54(5):537-45. doi: 10.1002/jcph.237. Epub 2013 Nov 30.
10
Simultaneous pharmacokinetic and pharmacodynamic modeling.药代动力学和药效学同步建模。
J Pharmacokinet Biopharm. 1981 Jun;9(3):367-88. doi: 10.1007/BF01059272.

本文引用的文献

1
Extending the code in the open-source saemix package to fit joint models of longitudinal and time-to-event data.将开源 saemix 包中的代码扩展以适应纵向和生存时间数据的联合模型。
Comput Methods Programs Biomed. 2024 Apr;247:108095. doi: 10.1016/j.cmpb.2024.108095. Epub 2024 Feb 23.
2
Evaluation of IPPSE, an alternative method for sequential population PKPD analysis.评估 IPPSE,一种用于序贯群体 PKPD 分析的替代方法。
J Pharmacokinet Pharmacodyn. 2012 Apr;39(2):177-93. doi: 10.1007/s10928-012-9240-x. Epub 2012 Jan 21.
3
Simultaneous vs. sequential analysis for population PK/PD data II: robustness of methods.群体药代动力学/药效学数据的同步分析与序贯分析II:方法的稳健性
J Pharmacokinet Pharmacodyn. 2003 Dec;30(6):405-16. doi: 10.1023/b:jopa.0000012999.36063.4e.
4
Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance.群体药代动力学/药效学数据的同步分析与序贯分析I:最佳情况表现
J Pharmacokinet Pharmacodyn. 2003 Dec;30(6):387-404. doi: 10.1023/b:jopa.0000012998.04442.1f.
5
The pharmacology of vascular smooth muscle.血管平滑肌的药理学
Pharmacol Rev. 1955 Jun;7(2):183-265.
6
Role of modelling and simulation in Phase I drug development.建模与模拟在药物研发I期的作用。
Eur J Pharm Sci. 2001 May;13(2):115-22. doi: 10.1016/s0928-0987(01)00096-3.
7
Comparison of four basic models of indirect pharmacodynamic responses.四种间接药效学反应基本模型的比较。
J Pharmacokinet Biopharm. 1993 Aug;21(4):457-78. doi: 10.1007/BF01061691.
8
Evaluation of methods for estimating population pharmacokinetic parameters. II. Biexponential model and experimental pharmacokinetic data.群体药代动力学参数估计方法的评估。II. 双指数模型与实验药代动力学数据
J Pharmacokinet Biopharm. 1981 Oct;9(5):635-51. doi: 10.1007/BF01061030.
9
Evaluation of methods for estimating population pharmacokinetics parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data.群体药代动力学参数估算方法的评估。I. 米氏模型:常规临床药代动力学数据。
J Pharmacokinet Biopharm. 1980 Dec;8(6):553-71. doi: 10.1007/BF01060053.
10
Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model: routine clinical pharmacokinetic data.群体药代动力学参数估计方法的评价。III. 单指数模型:常规临床药代动力学数据
J Pharmacokinet Biopharm. 1983 Jun;11(3):303-19. doi: 10.1007/BF01061870.

在药代动力学方法的摇篮中:介绍群体药代动力学-药效学建模、同步分析和效应室模型——对谢纳等人的评论

In the Cradle of Pharmacometric Methodology: Introducing Population PKPD Modeling, Simultaneous Analysis, and the Effect-Compartment Model-Commentary on Sheiner et al.

作者信息

Karlsson Mats O

机构信息

Department of Pharmacy, Uppsala University, Uppsala, Sweden.

出版信息

Clin Pharmacol Ther. 2025 Jun;117(6):1516-1532. doi: 10.1002/cpt.3663.

DOI:10.1002/cpt.3663
PMID:40388069
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12087688/
Abstract

In the decades preceding 1970s, there were considerable advances in theoretical descriptions of pharmacokinetics, drug action, and the time-course of dose-concentration-response relations. However, delayed drug effects and how to analyze data across individuals still offered a considerable challenge. Sheiner et al., through the formulation of the effect-compartment model, the utilization of nonlinear mixed effects models, and simultaneous PKPD analysis, offered solutions to these issues that still today are considered state-of-the-art.

摘要

在20世纪70年代之前的几十年里,药代动力学、药物作用以及剂量-浓度-反应关系的时程的理论描述取得了长足进展。然而,药物延迟效应以及如何对个体间的数据进行分析仍然是一个巨大的挑战。谢纳等人通过建立效应室模型、运用非线性混合效应模型以及同时进行药代动力学-药效学分析,为这些问题提供了至今仍被视为前沿的解决方案。